Interested in specific Information?

Filter what you see here

Relapsed/refractory patients

Quick poll

Jesus Berdeja | EHA 2018 | The CRB-401 phase I bb2121 CAR T-cell study

Jesus Berdeja | EHA 2018 | The CRB-401 phase I bb2121 CAR T-cell study

Closes Jun 17, 2018

Elderly patients

Quick poll

Sonja Zweegman | EHA 2018 | The issue of frailty in MM

Closes Jun 17, 2018

General MM

Quick poll

Paola Neri | EHA 2018 | The basis for immunotherapy in Multiple Myeloma

Closes Jun 16, 2018

General MM,   Patients eligible for transplant,  Patients non-eligible for transplant,   & 1 more

Quick poll

Niels Van de Donk | EHA 2018 | Immunotherapy in myeloma: why, when and how?

Niels Van de Donk | EHA 2018 | Immunotherapy in myeloma: why, when and how?

Closes Jun 15, 2018

Relapsed/refractory patients

Quick poll

ASCO 2018 | Updated results from the CRB-401 phase I study of bb2121 CAR…

Closes Jun 13, 2018

General MM,   Relapsed/refractory patients,  Patients eligible for transplant

Quick poll

ASCO 2018 | What happened with pembrolizumab in MM clinical trials?

Closes Jun 12, 2018

Relapsed/refractory patients

Quick poll

ASCO 2018 | Phase I trial of ruxolitinib, lenalidomide, and…

ASCO 2018 | Phase I trial of ruxolitinib, lenalidomide, and methylprednisolone for RRMM

Closes Jun 6, 2018

Quick poll

Rafael Fonseca | ASCO 2018 | Value and cost of myeloma therapy - we can…

Closes Jun 6, 2018

General MM

Quick poll

Vincent Rajkumar | ASCO 2018 | Value & cost of myeloma therapy - we…

Closes Jun 6, 2018

General MM

Quick poll

Philippe Moreau | ASCO 2018 | Critical trials in MM that could change…

Philippe Moreau | ASCO 2018 | Critical trials in MM that could change clinical practice

Closes Jun 5, 2018

Relapsed/refractory patients

Quick poll

ASCO 2018 | Phase III ARROW study: once weekly carfilzomib plus…

Closes Jun 4, 2018

General MM

Quick poll

COMy 2018 | Affordable and effective strategies in young patients: do they…

Closes Jun 2, 2018

General MM,   Relapsed/refractory patients

Quick poll

Maria Mateos | ASCO 2018 | Highlights of the randomized phase III…

Maria Mateos | ASCO 2018 | Highlights of the randomized phase III ARROW study 

Closes Jun 1, 2018

General MM,   Patients non-eligible for transplant,  Relapsed/refractory patients,  Patients eligible for transplant

Quick poll

COMy 2018 | Cytogenetics and genetics

Closes May 30, 2018

General MM

Quick poll

COMy 2018 | Quality of life considerations in myeloma

Closes May 29, 2018
A global online educational platform sharing the latest research and emerging treatment information in multiple myeloma

Latest Medical Information

Latest Publications

Latest Biology

Latest Drug Updates

Patients eligible for transplant,Patients non-eligible for transplant,Relapsed/refractory patients

Galinpepimut-S granted FDA orphan drug designation

May 11, 2018
Patients eligible for transplant,Patients non-eligible for transplant

Daratumumab approved by FDA for frontline use

May 8, 2018
Relapsed/refractory patients

Selinexor receives FDA fast track designation 

Apr 13, 2018

Recently updated Licenses

Where we are next

23rd Congress of the European Hematology Association (EHA)

June 14–17, 2018 | Stockholm, SE

The MM Hub will be attending the 23rd Congress of the European Hematology Association (EHA) to be held in Stockholm, Sweden, in June at the Stockholmsmässan conference center. The meeting prides itself on bringing together professionals worldwide to highlight 'state-of-the-art clinical practice and the latest findings in hematology research'. There will also be specialist satellite sessions and an exhibition hall. The program covers all hematological indications, including Multiple Myeloma (MM). Stay tuned to the MM Hub to follow our first-hand coverage.

#EHA23 #mmsm 

Event Website

Connect with us

Our sister hubs

Visit our other community physician education hubs in haematology and oncology